{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T20:18:42Z","timestamp":1788466722210,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100017531","name":"Medical and Health Research project of Zhejiang province","doi-asserted-by":"crossref","award":["Grant Number 2022KY279"],"award-info":[{"award-number":["Grant Number 2022KY279"]}],"id":[{"id":"10.13039\/501100017531","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Hangzhou Biomedical and Health Industry Development Support Science and Technology Special","award":["Grant Number 2023WJC023"],"award-info":[{"award-number":["Grant Number 2023WJC023"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-026-03393-2","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T19:48:01Z","timestamp":1788464881000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Low-dose rivaroxaban versus warfarin in Asian patients after surgical bioprosthetic valve replacement: a propensity score\u2013matched and inverse probability-weighted real-world study"],"prefix":"10.1007","author":[{"given":"Rui","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuyang","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leping","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"3393_CR1","doi-asserted-by":"crossref","unstructured":"Pibarot P, Dumesnil JG (2009) Prosthetic heart valves: selection of the optimal prosthesis and long-term management. Circulation United States 1034\u20131048","DOI":"10.1161\/CIRCULATIONAHA.108.778886"},{"issue":"17","key":"3393_CR2","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1016\/j.jacc.2017.02.051","volume":"69","author":"R Puri","year":"2017","unstructured":"Puri R, Auffret V, Rodes-Cabau J (2017) Bioprosthetic Valve Thrombosis. J Am Coll Cardiol 69(17):2193\u20132211. https:\/\/doi.org\/10.1016\/j.jacc.2017.02.051","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"3393_CR3","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1016\/j.jacc.2016.09.958","volume":"68","author":"GD Dangas","year":"2016","unstructured":"Dangas GD, Weitz JI, Giustino G, Makkar R, Mehran R (2016) Prosthetic Heart Valve Thrombosis. J Am Coll Cardiol 68(24):2670\u20132689. https:\/\/doi.org\/10.1016\/j.jacc.2016.09.958","journal-title":"J Am Coll Cardiol"},{"key":"3393_CR4","doi-asserted-by":"crossref","unstructured":"Brennan JM, Edwards FH, Zhao Y, O\u2019Brien S, Booth ME, Dokholyan RS et al (2012) Early anticoagulation of bioprosthetic aortic valves in older patients: results from the Society of Thoracic Surgeons Adult Cardiac Surgery National Database. J Am Coll Cardiol United States 971\u2013977","DOI":"10.1016\/j.jacc.2012.05.029"},{"issue":"5","key":"3393_CR5","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/0735-1097(94)00563-6","volume":"25","author":"M Heras","year":"1995","unstructured":"Heras M, Chesebro JH, Fuster V, Penny WJ, Grill DE, Bailey KR et al (1995) High risk of thromboemboli early after bioprosthetic cardiac valve replacement. J Am Coll Cardiol 25(5):1111\u20131119","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"3393_CR6","first-page":"e35","volume":"143","author":"CM Otto","year":"2021","unstructured":"Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JPR, Gentile F et al (2021) 2020 ACC\/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 143(5):e35\u2013e71","journal-title":"Circulation"},{"issue":"7","key":"3393_CR7","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","volume":"43","author":"A Vahanian","year":"2022","unstructured":"Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J et al (2022) 2021 ESC\/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 43(7):561\u2013632","journal-title":"Eur Heart J"},{"key":"3393_CR8","doi-asserted-by":"publisher","unstructured":"Praz F, Borger MA, Lanz J, Marin-Cuartas M, Abreu A, Adamo M et al (2025) 2025 ESC\/EACTS Guidelines for the management of valvular heart disease. Eur J Cardiothorac Surg 67(8). https:\/\/doi.org\/10.1093\/ejcts\/ezaf276","DOI":"10.1093\/ejcts\/ezaf276"},{"issue":"2","key":"3393_CR9","doi-asserted-by":"publisher","first-page":"e44S","DOI":"10.1378\/chest.11-2292","volume":"141","author":"W Ageno","year":"2012","unstructured":"Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G (2012) Oral Anticoagulant Therapy. Chest 141(2):e44S\u2013e88S. https:\/\/doi.org\/10.1378\/chest.11-2292","journal-title":"Chest"},{"issue":"6 Suppl","key":"3393_CR10","doi-asserted-by":"publisher","first-page":"160S","DOI":"10.1378\/chest.08-0670","volume":"133","author":"J Ansell","year":"2008","unstructured":"Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G (2008) Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(6 Suppl):160S\u201398S. https:\/\/doi.org\/10.1378\/chest.08-0670","journal-title":"Chest"},{"issue":"3","key":"3393_CR11","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.thromres.2009.02.012","volume":"125","author":"K Meijer","year":"2010","unstructured":"Meijer K, Kim YK, Schulman S (2010) Decreasing warfarin sensitivity during the first three months after heart valve surgery: Implications for dosing. Thromb Res 125(3):224\u2013229. https:\/\/doi.org\/10.1016\/j.thromres.2009.02.012","journal-title":"Thromb Res"},{"key":"3393_CR12","doi-asserted-by":"crossref","unstructured":"Zhao M, Lip GY (2025) Stroke and bleeding risks in Asian and non-Asian patients with atrial fibrillation: further insights into the \u2018East Asian Paradox\u2019. Open Heart. vol 1. England","DOI":"10.1136\/openhrt-2024-003122"},{"issue":"2","key":"3393_CR13","doi-asserted-by":"publisher","first-page":"e105575","DOI":"10.1136\/bmjopen-2025-105575","volume":"16","author":"C Wang","year":"2026","unstructured":"Wang C, Luo J, Zhou X, Guo Y, Cao W, Zhang D et al (2026) Evaluation of a pharmacist-led patient-self-testing model for warfarin management in patients undergoing mechanical heart valve replacement in China: a multicentre, open-label, randomised, controlled trial. BMJ Open 16(2):e105575. https:\/\/doi.org\/10.1136\/bmjopen-2025-105575","journal-title":"BMJ Open"},{"key":"3393_CR14","doi-asserted-by":"crossref","unstructured":"Liang HF, Du X, Zhou YC, Yang XY, Xia SJ, Dong JZ et al (2019) Control of Anticoagulation Therapy in Patients with Atrial Fibrillation Treated with Warfarin: A Study from the Chinese Atrial Fibrillation Registry. Med Sci Monit United States 4691\u20134698","DOI":"10.12659\/MSM.917131"},{"key":"3393_CR15","doi-asserted-by":"crossref","unstructured":"Steffel J, Heidbuchel H (2021) 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: comment-Authors\u2019 reply. Europace Engl 1685\u20131686","DOI":"10.1093\/europace\/euab218"},{"key":"3393_CR16","doi-asserted-by":"crossref","unstructured":"Mueck W, Stampfuss J, Kubitza D, Becka M (2014) Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet Switz 1\u201316","DOI":"10.1007\/s40262-013-0100-7"},{"issue":"22","key":"3393_CR17","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa2029603","volume":"383","author":"HP Guimaraes","year":"2020","unstructured":"Guimaraes HP, Lopes RD, de Barros ESPGM, Liporace IL, Sampaio RO, Tarasoutchi F et al (2020) Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve. N Engl J Med 383(22):2117\u20132126","journal-title":"N Engl J Med"},{"issue":"7","key":"3393_CR18","doi-asserted-by":"publisher","first-page":"e015108","DOI":"10.1161\/CIRCINTERVENTIONS.124.015108","volume":"18","author":"C Izumi","year":"2025","unstructured":"Izumi C, Amano M, Yoshikawa Y, Fukushima S, Yaku H, Eishi K et al (2025) Efficacy and Safety of Edoxaban in Anticoagulant Therapy Early After Surgical Bioprosthetic Valve Replacement: A Randomized Clinical Trial. Circ Cardiovasc Interv 18(7):e015108. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.124.015108","journal-title":"Circ Cardiovasc Interv"},{"issue":"1","key":"3393_CR19","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jtcvs.2021.01.127","volume":"165","author":"CY Shim","year":"2023","unstructured":"Shim CY, Seo J, Kim YJ, Lee SH, De Caterina R, Lee S et al (2023) Efficacy and safety of edoxaban in patients early after surgical bioprosthetic valve implantation or valve repair: A randomized clinical trial. J Thorac Cardiovasc Surg 165(1):58\u201367e4. https:\/\/doi.org\/10.1016\/j.jtcvs.2021.01.127","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"9","key":"3393_CR20","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1253\/circj.CJ-12-0454","volume":"76","author":"M Hori","year":"2012","unstructured":"Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S et al (2012) Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation - the J-ROCKET AF study. Circ J 76(9):2104\u20132111","journal-title":"Circ J"},{"key":"3393_CR21","doi-asserted-by":"crossref","unstructured":"Liu XQ, Li ZR, Wang CY, Chen YT, Jiao Z (2023) Is a Lower Dose of Rivaroxaban Required for Asians? A Systematic Review of a Population Pharmacokinetics and Pharmacodynamics Analysis of Rivaroxaban. Pharmaceutics. Switzerland","DOI":"10.3390\/pharmaceutics15020588"},{"key":"3393_CR22","doi-asserted-by":"publisher","unstructured":"Eikelboom R, Whitlock RP, Muzaffar R, Lopes RD, Siegal D, Schulman S et al (2023) Direct oral anticoagulants versus vitamin K antagonists in the first 3 months after bioprosthetic valve replacement: a systematic review and meta-analysis. Eur J Cardiothorac Surg 63(4). https:\/\/doi.org\/10.1093\/ejcts\/ezad110","DOI":"10.1093\/ejcts\/ezad110"},{"issue":"38","key":"3393_CR23","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3760\/cma.j.cn112434-20220126-00028","volume":"3","author":"The Group Of Valve Surgery CSFT","year":"2022","unstructured":"The Group Of Valve Surgery CSFT (2022) Consensus of Chinese experts on anticoagulant therapy in cardiac valve survey. Chin J Thorac Cardiovasc Surg 3(38):164\u2013174. https:\/\/doi.org\/10.3760\/cma.j.cn112434-20220126-00028","journal-title":"Chin J Thorac Cardiovasc Surg"},{"key":"3393_CR24","doi-asserted-by":"crossref","unstructured":"Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost Engl 692\u2013694","DOI":"10.1111\/j.1538-7836.2005.01204.x"},{"issue":"11","key":"3393_CR25","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1111\/jth.13140","volume":"13","author":"S Kaatz","year":"2015","unstructured":"Kaatz S, Ahmad D, Spyropoulos AC, Schulman S (2015) Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non\u2010surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 13(11):2119\u20132126. https:\/\/doi.org\/10.1111\/jth.13140","journal-title":"J Thromb Haemost"},{"issue":"2","key":"3393_CR26","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s11739-023-03208-9","volume":"18","author":"S Galliazzo","year":"2023","unstructured":"Galliazzo S, Pelitti V, Campiotti L, Poli D, Squizzato A (2023) Direct oral anticoagulants in patients with a left-sided bioprosthetic heart valve: a systematic review and meta-analysis. Intern Emerg Med 18(2):535\u2013547","journal-title":"Intern Emerg Med"},{"key":"3393_CR27","doi-asserted-by":"crossref","unstructured":"Hirsh J, Fuster V, Ansell J, Halperin JL (2003) American Heart Association\/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol United States 1633\u20131652","DOI":"10.1161\/01.CIR.0000063575.17904.4E"},{"key":"3393_CR28","doi-asserted-by":"crossref","unstructured":"Witt DM, Clark NP, Kaatz S, Schnurr T, Ansell JE (2016) Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism. J Thromb Thrombolysis Neth 187\u2013205","DOI":"10.1007\/s11239-015-1319-y"},{"key":"3393_CR29","doi-asserted-by":"crossref","unstructured":"Tanigawa T, Kaneko M, Hashizume K, Kajikawa M, Ueda H, Tajiri M et al (2013) Model-based dose selection for phase III rivaroxaban study in Japanese patients with non-valvular atrial fibrillation. Drug Metab Pharmacokinet Engl 59\u201370","DOI":"10.2133\/dmpk.DMPK-12-RG-034"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-026-03393-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-026-03393-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-026-03393-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T19:48:05Z","timestamp":1788464885000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-026-03393-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":29,"alternative-id":["3393"],"URL":"https:\/\/doi.org\/10.1007\/s11239-026-03393-2","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"assertion":[{"value":"26 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study complies with the Declaration of Helsinki and its later amendments or comparable ethical standards and was approved by the Institutional Review Board of the Zhejiang Provincial People's Hospital (Approved No. of ethics committee: MR-33-24-034641).","order":2,"name":"Ethics","label":"Ethical","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The requirement for informed consent was waived by the Institutional Review Board because of the retrospective nature of the study.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}